Takeda Pharmaceutical Company (TAK) has released promising results from two pivotal Phase 3 studies of its oral tyrosine kinase 2 (TYK2) inhibitor, zasocitinib (TAK-279), aimed at treating moderate-to-severe plaque psoriasis. The data indicates that approximately 70% of patients achieved clear or nearly clear skin by week 16, with significant improvements noted as early as week 4. The safety profile aligns with previous studies, reinforcing the drug’s potential for rapid efficacy.

This development is crucial for Takeda as it prepares to submit a New Drug Application (NDA) to the FDA and other regulatory bodies in fiscal year 2026. While the company stated that these results will not significantly affect its financial outlook for the fiscal year ending March 31, 2026, the ongoing advancements in its pipeline could enhance investor confidence and influence stock performance.

Market professionals should monitor Takeda’s progress with zasocitinib, as successful regulatory approval could position the company favorably within the competitive dermatology market, potentially driving future revenue growth.

Source: nasdaq.com